Watching WEST PHARMACEUTICAL SERVICES, INC.? See every signal — funding, hires, M&A, contracts, sentiment.
Book a demoChoose your planWEST PHARMACEUTICAL SERVICES, INC.
westpharma.comAI Executive Summary
AI-powered analysis of 8-K filing content
West Pharmaceutical Services finalized an Amended and Restated Technology Exchange and Crosslicense Agreement with Daikyo Seiko, Ltd., along with two Distributorship Agreements effective July 14, 2026, strengthening their long-standing partnership and enhancing technology exchange and distribution capabilities.
Key Takeaways
West Pharmaceutical Services renewed and amended its technology exchange and crosslicense agreement with Daikyo Seiko, building on a relationship that began in January 2017
The company holds a 49% ownership interest in Daikyo Seiko, indicating a significant strategic partnership and joint venture structure
2 more takeaways
Related Filings (1)
1 more filing from WEST PHARMACEUTICAL SERVICES, INC. in the last 90 days